相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia
Fabrice Usseglio et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology
Paola Guglielmelli et al.
LEUKEMIA RESEARCH (2017)
Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR
Miguel Waterhouse et al.
ANNALS OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
JAK2V617F allele burden ≥50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
G. Barosi et al.
LEUKEMIA (2016)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis
Eric Lippert et al.
HAEMATOLOGICA (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
Myelofibrotic Transformations of Polycythemia Vera and Essential Thrombocythemia are Morphologically, Biologically, and Prognostically Indistinguishable From Primary Myelofibrosis
Nikhil Sangle et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2014)
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
Anthony J. Bench et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse
Thoralf Lange et al.
HAEMATOLOGICA (2013)
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
J. V. Jovanovic et al.
LEUKEMIA (2013)
JAK2V617F allele burden is associated with transformation to myelofibrosis
Maya Koren-Michowitz et al.
LEUKEMIA & LYMPHOMA (2012)
Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
Nicholas C. P. Cross
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment
Alessandro M. Vannucchi et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2011)
Mutational Status of Myeloproliferative Neoplasms
Elisa Rumi et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2010)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
Paola Guglielmelli et al.
BLOOD (2009)
JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation
Nicolaus Kroeger et al.
BLOOD (2009)
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
Philip A. Beer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
Stephen A. Bustin et al.
CLINICAL CHEMISTRY (2009)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Clinical implications of JAK2 mutations in myeloproliferative disorders
L. Knoops et al.
ACTA CLINICA BELGICA (2008)
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
Elisabetta Antonioli et al.
HAEMATOLOGICA (2007)
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype
Thomas Stauffer Larsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders
Thomas Stauffer Larsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and NIMM patients with clonal hematopoiesis
Ross L. Levine et al.
BLOOD (2006)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
F Passamonti et al.
BLOOD (2006)
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
A Tefferi et al.
CANCER (2006)
The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors
P. Sidon et al.
LEUKEMIA (2006)
The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:: lineage specificity and clinical correlates
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
分享论文
